Clinical trials: Docetaxel
HER2-positive Breast Cancer
De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients
Neoadjuvant therapy is currently the standard treatment process for locally advanced breast cancer, especially for human epidermal growth factor receptor 2 (HER2) positive and triple negative breast cancer, which meets the…
- Trial name
- NacHER2 (NCT06700369)
- Where
- China
- Volunteers
- 519 people
- Sponsor
- Shu Wang
Carcinoma, Non-Small-Cell Lung
Once Weekly Radiation for Lung Cancer With Chemotherapy
This program is designed for the treatment of patients with advanced non-small cell lung cancer. The study is designed for patients whose cancer is too advanced and therefore cannot be operated with the goal of completely…
- Trial name
- NCT00256789
- Testing
- Radiation, Chemotherapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Clinical Oncology Research Associates
Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy
This is a Phase 3, open-label single-arm trial designed to evaluate the safety and efficacy of NDV-01 (sustained-release gemcitabine-docetaxel) in adult participants with NMIBC with CIS who have failed BCG therapy and who have…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
- Trial name
- RESCUE (NCT07342517)
- Testing
- NDV-01 (sustained-release gemcitabine-docetaxel)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Relmada Therapeutics, Inc.
Testicular Cancer
High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors
The goal of this clinical research study is to learn if 2 cycles of high-dose chemotherapy can help to control germ-cell tumors.
- Trial name
- NCT00936936
- Testing
- Gemcitabine, Docetaxel, Melphalan
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Hyperthermic Intraperitoneal Chemotherapy, Neoadjuvant Chemotherapy
Efficacy of Neoadjuvant Hyperthermic Intraperitoneal Chemotherapy in Advanced High-grade Serous Ovarian Cancer (the NHIPEC Trial)
Background: Neoadjuvant chemotherapy (NACT) is an important treatment option for patients with ovarian cancer. Although intravenous NACT can improve optimal resection rates and decrease surgical morbidity and mortality, these…
- Trial name
- NHIPEC (NCT05246020)
- Testing
- HIPEC, intravenous chemotherapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Thoracic Esophageal Squamous Cell Carcinoma
Improve the Treatment of Thoracic Esophageal Cancer
The purpose of this study is 1. To compare the effects of the two types of thoracic esophageal cancer lymphadenectomy on the staging and prognosis of resectable esophageal cancer, which defined by the International Association of…
- Trial name
- NCT01137123
- Testing
- adjuvant chemotherapy, standard two field Lymphadenectomy, Total two field Lymphadenectomy
- Where
- China
- Volunteers
- 301 people
- Sponsor
- Sun Yat-sen University
Prostatic Neoplasms
Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer
The primary objective of this study was to determine the safety and Maximum tolerated dose (MTD) of BIBF 1120 combination therapy with docetaxel and prednisone in patients with hormone refractory prostate cancer.
- Trial name
- NCT02182219
- Testing
- BIBF 1120
- Volunteers
- 21 people
- Sponsor
- Boehringer Ingelheim
Prostate Cancer
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
VA Cooperative Study #553 is designed to prospectively evaluate the efficacy of early adjuvant chemotherapy using docetaxel and prednisone added to the standard of care for patients who are potentially cured by radical…
- Trial name
- CAP (NCT00132301)
- Testing
- Docetaxel, Prednisone
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 298 people
- Sponsor
- VA Office of Research and Development
Nasopharyngeal Carcinoma
Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes
Patients have a type of cancer called nasopharyngeal carcinoma (NPC) that has either come back or not gone away after the best known standard treatments.
- Trial name
- CADEN (NCT00953420)
- Testing
- Docetaxel, Carboplatin, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Baylor College of Medicine
Prostate Cancer
Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
Primary Objective: 1. To evaluate the pathological complete response rate to neoadjuvant hormonal ablation, Imatinib and Docetaxel (HID) in high-risk localized prostate cancer. Secondary Objectives: 1.
- Trial name
- NCT00500110
- Testing
- Docetaxel, Imatinib Mesylate, Leuprolide
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- M.D. Anderson Cancer Center
Synovial Sarcoma
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma
This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory synovial sarcoma (SS) in children and young adults.
- Trial name
- NCT04145700
- Testing
- Ramucirumab, Gemcitabine, Docetaxel
- Where
- 56 sites in United States, Australia and 8 more
- Volunteers
- 23 people
- Sponsor
- Eli Lilly and Company
Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
This is an open label, two-stratum, phase 2 clinical trial evaluating the efficacy of 9-ING-41 in combination with gemcitabine/docetaxel in patients ≥10 years of age with advanced sarcoma.
- Conditions
- Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, Leiomyosarcoma
- Trial name
- NCT05116800
- Testing
- Gemcitabine, 9-ING-41, Docetaxel
- Where
- 2 sites in United States
- Sponsor
- Brown University
Cancer
Weekly Administration of (bi-)Daily Oral Docetaxel in Combination With Ritonavir
Oral administration has many advantages above intravenously administrated drugs for patients. Up to now, oral administration of docetaxel as single agent has not been feasible due to low and variable bioavailability.
- Trial name
- NCT01173913
- Testing
- ModraDoc001 10mg capsules, ModraDoc003 10mg tablets and ModraDoc004 10/50 mg, ModraDoc006 10 mg tablet
- Where
- Netherlands
- Volunteers
- 57 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer, Docetaxel Chemotherapy
A Trial of Evonail® Solution for Prevention or Treatment of Onycholysis
This study is a prospective randomized controlled study of EVONAIL® solution for prevention or treatment of onycholysis in patients with breast cancer receiving docetaxel chemotherapy.
- Trial name
- NCT02670603
- Testing
- EVONAIL® solution
- Where
- South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Osteosarcoma
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure
This is a randomized, controlled, open, multicenter phase III clinical study to evaluate the efficacy and safety of HS-20093 for injection versus gemcitabine in combination with docetaxel in patients with osteosarcoma who have at…
- Trial name
- NCT06935409
- Testing
- HS-20093, Gemcitabine combined with docetaxel
- Where
- 2 sites in China
- Volunteers
- 122 people
- Sponsor
- Hansoh BioMedical R&D Company
Lung Cancer, Soft Tissue Sarcoma
Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer
To determine the molecular interaction in tumor samples between docetaxel and lonafarnib.
- Conditions
- Lung Cancer, Soft Tissue Sarcoma, Colorectal Carcinoma, Breast Cancer
- Trial name
- NCT00288444
- Testing
- Lonafarnib, Docetaxel
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Emory University
Metastatic Castration-Resistant Prostate Cancer
Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
The purpose of this treatment protocol is to provide expanded access to MDV3100 and monitor its safety in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy.
- Trial name
- NCT01606982
- Testing
- MDV3100
- Sponsor
- Astellas Pharma Global Development, Inc.
Nasopharyngeal Neoplasms, Carcinoma
Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents
The primary objective is to estimate the Complete Response rate of docetaxel to the combination of cisplatin-5-fluorouracil (TCF) compared to cisplatin-5-fluorouracil (CF) in the Induction treatment of Nasopharyngeal Carcinoma…
- Trial name
- NCT00565448
- Testing
- docetaxel, cisplatin, 5-fluorouracil
- Where
- 26 sites in Algeria, Brazil and 12 more
- Volunteers
- 75 people
- Sponsor
- Sanofi
Prostate Cancer
Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer
The goal of this clinical research study is to find out if a therapy using docetaxel chemotherapy with hormonal therapy taken before your scheduled surgery is beneficial to treatment of prostate cancer.
- Trial name
- NCT01076335
- Testing
- Neoadjuvant Hormonal Therapy, Docetaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Heart Failure
Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
Trastuzumab is an important treatment for HER 2 positive breast cancer. But trastuzumab can cause injury to the heart, and this is one of the main reasons it cannot be administered as planned.
- Trial name
- SCHOLAR-2 (NCT04680442)
- Testing
- Trastuzumab, Pertuzumab, Trastuzumab emtansine
- Where
- 8 sites in Brazil, Canada and 1 more
- Volunteers
- 130 people
- Sponsor
- Population Health Research Institute